Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Amit Sanyal, MD: A Clinician’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Jan
13
Today In Oncology
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Can KDM6A Mutations Help Guide Treatment Selection in Bladder Cancer
Anaplastic Glioma Concurrent vs Adjuvant Temozolomide
Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer
Refractory LBCL CD19-Targeting CAR T-Cell Therapy Plus Rituximab
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo